Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baloxavir plus neuraminidase inhibitor versus neuraminidase inhibitor alone in hospitalized severe influenza
NL-OMON48962Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing Baloxavir marboxil + SOC neuraminidase inhibitor with Placebo + SOC neuraminidase inhibitor (2 arms). Primary endpoint: Time to clinical improvement. Started Dec 2019; status: active, not recruiting.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON48962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48962.